Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Bought by Marshall Wace LLP

Marshall Wace LLP lifted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 87.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 5,155,402 shares of the company's stock after acquiring an additional 2,410,420 shares during the quarter. Marshall Wace LLP owned approximately 0.46% of Teva Pharmaceutical Industries worth $113,625,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in TEVA. Stifel Financial Corp grew its stake in Teva Pharmaceutical Industries by 54.0% in the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company's stock valued at $1,196,000 after buying an additional 23,283 shares in the last quarter. Orion Portfolio Solutions LLC bought a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at $198,000. Barclays PLC lifted its holdings in Teva Pharmaceutical Industries by 31.7% during the 3rd quarter. Barclays PLC now owns 427,595 shares of the company's stock worth $7,705,000 after purchasing an additional 102,848 shares in the last quarter. Sanctuary Advisors LLC boosted its stake in Teva Pharmaceutical Industries by 1.9% in the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock worth $601,000 after purchasing an additional 664 shares during the period. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of Teva Pharmaceutical Industries during the third quarter valued at about $50,000. Hedge funds and other institutional investors own 54.05% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on TEVA shares. Piper Sandler upped their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. UBS Group reduced their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Bank of America dropped their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. StockNews.com cut Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Monday, April 14th. Finally, Barclays cut their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $23.43.

Teva Pharmaceutical Industries Stock Up 4.2 %

Shares of TEVA traded up $0.56 during mid-day trading on Tuesday, reaching $13.87. The company had a trading volume of 3,982,271 shares, compared to its average volume of 9,888,475. The firm has a 50-day moving average price of $15.39 and a 200 day moving average price of $17.65. The company has a market capitalization of $15.73 billion, a price-to-earnings ratio of -9.56, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a 52 week low of $12.47 and a 52 week high of $22.80. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, sell-side analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.